What GSK drug significantly contributed to its 2021 Covid sales?

Question

Accepted Answer

GSK's Covid-19 Antibody Drug Drives Significant 2021 Sales

GSK's Covid-related sales in 2021 reached £1.4 billion (RM7.94 billion), with the antibody drug sotrovimab being the primary contributor to this revenue. This significant contribution was driven by the drug's efficacy against the Omicron variant, leading to substantial sales growth, particularly in the latter half of the year.
Sotrovimab's Strong Sales Performance

The antibody drug sotrovimab, developed in partnership with Vir Biotechnology, was instrumental in GSK's 2021 Covid-related sales. Sales of sotrovimab, marketed as Xevudy, reached £828 million in the fourth quarter of 2021. This figure represented a substantial increase from the £114 million recorded in the third quarter of the same year, exceeding market expectations of £774 million for the period.
Efficacy Against Omicron Variant

Sotrovimab's effectiveness against the fast-spreading Omicron variant played a crucial role in its high demand and subsequent sales performance. As one of the few Covid-19 treatments demonstrating efficacy against this particular variant, it became a key therapeutic option, bolstering its market position and contributing significantly to GSK's revenue streams throughout 2021.
Projected 2022 Sales and Profit Margins

Looking ahead, GSK anticipated that its pandemic-related sales in 2022 would remain at similar levels to those achieved in 2021. However, the company also indicated that these sales would contribute less to overall profit. This projected decrease in profit contribution was attributed to lower profit margins associated with its antibody treatments, including sotrovimab.

Reading history

Hide →

This history is cleared when the page is closed.

What GSK drug significantly contributed to its 2021 Covid sales?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends